<DOC>
	<DOCNO>NCT01868555</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial ass safety , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) two insulin degludec/insulin aspart ( IDegAsp ) preparation two insulin degludec ( insulin 454 ) preparation healthy Japanese male subject . IDegAsp 45 ( B ) insulin degludec ( B ) explorative formulation , similar propose commercial formulation .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics Two IDegAsp ( One Explorative ) Preparations Two Insulin Degludec ( One Explorative ) Preparations Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Healthy Japanese male subject Body mass index ( BMI ) 18.0 27.0 kg/m^2 ( inclusive ) Body weight equal 50 kg The receipt investigational drug within 16 week prior trial ( plan first dose ) Any clinical laboratory value deviate reference range laboratory ( except case within physiological change ) abnormal electrocardiogram ( ECG ) finding screen , judge investigator subinvestigator Known suspect allergy trial product ( ) relate product</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>